Raise Series B · $60M · announced Sep 22, 2025 Company release ↗Source quote
Sep 22, 2025 · Company release ↗ “Avenzo Therapeutics Announces $60 Million Series B Financing”
Raise Series A · amount not disclosed · announced Nov 18, 2024 Company release ↗Source quote
Nov 18, 2024 · Company release ↗ “In addition, Avenzo has closed the final tranche of an oversubscribed Series A/A-1 financing, adding three new investors.”
Deal Gilead deal · amount not disclosed · announced Sep 3, 2024 Company release ↗Source quote
Sep 3, 2024 · Company release ↗ “Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer”
Raise Series A · $150M · announced Mar 26, 2024 Company release ↗Source quote
Mar 26, 2024 · Company release ↗ “Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline”
Raises announced in these releases: $210M disclosed.
Trial start Phase 1/Phase 2: BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) source ↗
Trial start Phase 1/Phase 2: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors source ↗
Trial start Phase 1/Phase 2: AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) source ↗
Trial start Phase 1/Phase 2: Study of AVZO-021 in Patients With Advanced Solid Tumors source ↗
Upcoming milestones
Jan 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Study of AVZO-021 in Patients With Advanced Solid Tumors · NCT05867251
2028-08 (ESTIMATED) · Phase 1/Phase 2 · ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors · NCT06998407
2030-03 (ESTIMATED) · Phase 1/Phase 2 · BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) · NCT07193511
2030-06 (ESTIMATED) · Phase 1/Phase 2 · AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) · NCT07038343
Estimated primary completion per ClinicalTrials.gov. Dates move.
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.